Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 18/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 18/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 18/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 16/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 16/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 16/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 16/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 16/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 16/20 | 0.49 |
| ▸ | HDAC9 | Q9UKV0 | 16/20 | 0.49 |
| ▸ | HDAC5 | Q9UQL6 | 16/20 | 0.49 |
| ▸ | NAMPT | P43490 | 3/20 | 0.44 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27183478 | 1.00 | HDAC3 (0.49) | HDAC3HDAC1HDAC2HDAC4HDAC7 | |
| SCHEMBL26108499 | 0.85 | FOLH1 (0.41) | HDAC3HDAC1HDAC2HDAC4HDAC7 | |
| SCHEMBL26527860 | 0.85 | FOLH1 (0.41) | HDAC3HDAC1HDAC2HDAC4HDAC7 | |
| SCHEMBL26108502 | 0.85 | FOLH1 (0.41) | HDAC3HDAC1HDAC2HDAC4HDAC7 | |
| SCHEMBL24642649 | 0.80 | EGLN1 (0.38) | — | |
| SCHEMBL26109623 | 0.79 | HDAC3 (0.42) | HDAC3HDAC1HDAC2HDAC4HDAC7 | |
| SCHEMBL26108152 | 0.79 | EPHX2 (0.47) | HDAC3HDAC1HDAC2HDAC4HDAC7 | |
| SCHEMBL26527855 | 0.76 | EGLN1 (0.35) | — | |
| SCHEMBL28872459 | 0.75 | HDAC3 (0.50) | HDAC3HDAC1HDAC2HDAC4HDAC7 | |
| SCHEMBL24642914 | 0.75 | ITGB1 (0.42) | HDAC3HDAC1HDAC2HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240108745-A1 | BIOACTIVE SUBSTANCE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | MEDILINK THERAPEUTICS (SUZHOU) CO., LTD. (CN) | 2024-04-04 | — | — | US | disclosed |
| EP-4257154-A1 | BIOACTIVE SUBSTANCE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | Medilink Therapeutics (Suzhou) Co., Ltd. (CN) | 2023-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240108745-A1 | BIOACTIVE SUBSTANCE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | CTSL, VIP, FURIN | HDAC3 4136/4885HDAC1 2969/4885HDAC2 4011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.